Skip to main content
Premium Trial:

Request an Annual Quote

Soren Germer, Michael Zody, Ana Bastiani-Posner

Soren Germer has been promoted to senior VP of genome technologies of the New York Genome Center. He previously served as the center's senior scientific director of sequencing operations, and before that, sequencing program manager. In his new role, Germer will lead the activities of the NYGC's sequencing and analysis teams.

Also, Michael Zody has been promoted to scientific director of computational biology of the NYGC, a new role. Zody will continue to provide scientific leadership to the computational biology team as well as lead new grants, foster partnerships, and serve as strategic scientific advisor.

In addition, Ana Bastiani-Posner has joined the NYGC as senior VP of finance and administration. Previously, she held executive finance roles at Allergan, Novartis Pharmaceuticals, and Schering-Plough.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.